MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company was founded in 1991 and is headquartered in Westlake Village, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MNKD
CUSIP56400P20
Phone818-661-5000
Debt
Debt-to-Equity Ratio-0.43
Current Ratio0.43
Quick Ratio0.39
Price-To-Earnings
Trailing P/E Ratio-1.67
Forward P/E Ratio-2.34
P/E GrowthN/A
Sales & Book Value
Annual Sales$11.74 million
Price / Sales23.14
Cash FlowN/A
Price / CashN/A
Book Value($1.81) per share
Price / Book-1.07
Profitability
EPS (Most Recent Fiscal Year)($1.16)
Net Income$-117,330,000.00
Net Margins-1,076.91%
Return on EquityN/A
Return on Assets-185.01%
Miscellaneous
Employees250
Outstanding Shares140,020,000
MannKind (NASDAQ:MNKD) Frequently Asked Questions
What is MannKind's stock symbol?
MannKind trades on the NASDAQ under the ticker symbol "MNKD."
How were MannKind's earnings last quarter?
MannKind Co. (NASDAQ:MNKD) issued its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.02. The biopharmaceutical company earned $3.47 million during the quarter, compared to analyst estimates of $3.53 million. During the same period last year, the firm earned ($0.17) EPS. View MannKind's Earnings History.
When is MannKind's next earnings date?
What price target have analysts set for MNKD?
2 equities research analysts have issued 1 year target prices for MannKind's stock. Their predictions range from $1.00 to $5.00. On average, they expect MannKind's share price to reach $2.9233 in the next year. View Analyst Ratings for MannKind.
What are Wall Street analysts saying about MannKind stock?
Here are some recent quotes from research analysts about MannKind stock:
- 1. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (5/24/2018)
- 2. HC Wainwright analysts commented, "Exchange NASDAQ Value (M) $324.5 Market Cap (M) $238 Shares Outstanding (M) 133.1 3 Interest (M) 32.53 Cash (M) $53.5 Total Debt (M) $140.0 Year – (0.15) FY (1.13) (0.83) (0.65) FY P/E NM NM NM Year – 14.7 FY 11.7 20.8 45.4 8 6 4 2 0 0 Vol. (mil) the science to drive Afrezza awareness and adoption." (5/10/2018)
Are investors shorting MannKind?
MannKind saw a decrease in short interest in the month of May. As of May 31st, there was short interest totalling 29,044,004 shares, a decrease of 4.0% from the May 15th total of 30,255,708 shares. Based on an average trading volume of 1,761,471 shares, the short-interest ratio is presently 16.5 days. Approximately 23.0% of the company's stock are sold short.
Who are some of MannKind's key competitors?
Some companies that are related to MannKind include TG Therapeutics Inc common stock (TGTX), Epizyme (EPZM), Reata Pharmaceuticals (RETA), Dynavax Technologies (DVAX), Endocyte (ECYT), Flexion Therapeutics (FLXN), Vanda Pharmaceuticals (VNDA), CytomX Therapeutics (CTMX), Arrowhead Pharmaceuticals (ARWR), Assembly Biosciences (ASMB), Omeros (OMER), MacroGenics (MGNX), Amarin (AMRN), Karyopharm Therapeutics (KPTI) and OptiNose (OPTN).
Who are MannKind's key executives?
MannKind's management team includes the folowing people:
- Dr. Michael E. Castagna, CEO & Director (Age 41)
- Dr. David B. Thomson, Gen. Counsel & Corp. Sec. (Age 51)
- Mr. Steven B. Binder, Chief Financial Officer (Age 55)
- Mr. Joseph Kocinsky, Chief Technology Officer (Age 54)
- Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 57)
Has MannKind been receiving favorable news coverage?
Headlines about MNKD stock have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MannKind earned a media sentiment score of 0.20 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.10 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are MannKind's major shareholders?
MannKind's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (5.57%), BlackRock Inc. (2.62%), Scopia Capital Management LP (0.81%), Millennium Management LLC (0.74%), Tibra Equities Europe Ltd (0.20%) and Dupont Capital Management Corp (0.20%). Company insiders that own MannKind stock include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Raymond W Urbanski, Rosabel Realica Alinaya and Stuart A Tross. View Institutional Ownership Trends for MannKind.
Which major investors are selling MannKind stock?
Which major investors are buying MannKind stock?
MNKD stock was acquired by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Millennium Management LLC, Tibra Equities Europe Ltd, Element Capital Management LLC, Dupont Capital Management Corp and Schwab Charles Investment Management Inc.. Company insiders that have bought MannKind stock in the last two years include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Rosabel Realica Alinaya and Stuart A Tross. View Insider Buying and Selling for MannKind.
How do I buy shares of MannKind?
Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MannKind's stock price today?
One share of MNKD stock can currently be purchased for approximately $1.94.
How big of a company is MannKind?
MannKind has a market capitalization of $266.05 million and generates $11.74 million in revenue each year. The biopharmaceutical company earns $-117,330,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. MannKind employs 250 workers across the globe.
How can I contact MannKind?
MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 301, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]
MarketBeat Community Rating for MannKind (MNKD)
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe MNKD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days.
